GO:2000301 negative regulation of synaptic vesicle exocytosis: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000301 describes any process that stops, prevents, or reduces the frequency, rate, or extent of synaptic vesicle exocytosis.
• Key molecular players include syntaxin-1A, Munc18, Gβγ subunits, CAPS-1, SV2A, and VGLUT2, which modulate vesicle fusion and recycling.
• Dysregulation of this process is implicated in schizophrenia and other synaptic disorders.
• The term is a biological process node in the Gene Ontology, distinct from positive regulation or the exocytosis process itself.
• Research methods to study GO:2000301 include electrophysiology, live-cell imaging, and genetic perturbation via CRISPR.
• Understanding negative regulation is critical for therapeutic targeting of synaptic dysfunction in neurological and psychiatric diseases.
Description
Synaptic vesicle exocytosis is the fundamental process by which neurons release neurotransmitters into the synaptic cleft, enabling communication across synapses. The frequency and extent of this release must be tightly controlled to maintain proper neural circuit function. GO:2000301, negative regulation of synaptic vesicle exocytosis, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of synaptic vesicle exocytosis. This regulatory node is essential for preventing excessive neurotransmitter release, which can lead to excitotoxicity, and for fine-tuning synaptic plasticity. Researchers study this term to understand how neurons maintain balance in synaptic transmission and how disruptions contribute to disease. Key molecular players include SNARE proteins, their regulators such as Munc18 and syntaxin-1A, G-protein subunits, and vesicle-associated proteins like SV2A and CAPS-1. The importance of this process extends to neurological and psychiatric disorders, where synaptic dysfunction is a common theme. By dissecting the mechanisms of negative regulation, scientists can identify targets for therapeutic intervention in conditions such as schizophrenia, epilepsy, and neurodegenerative diseases.
negative regulation of synaptic vesicle exocytosis At A Glance
| GO ID | GO:2000301 |
|---|---|
| GO term | negative regulation of synaptic vesicle exocytosis |
| Ontology | biological_process |
| Synonym | none |
| Major function | Inhibits or reduces the frequency, rate, or extent of synaptic vesicle exocytosis |
| Related processes | Synaptic vesicle exocytosis (GO:0006887), regulation of synaptic vesicle exocytosis (GO:2000300) |
| Key regulators | Syntaxin-1A, Munc18, Gβγ, CAPS-1, SV2A, VGLUT2 |
| Disease relevance | Schizophrenia, synaptic dysfunction, potential roles in other neurological disorders |
What Is GO:2000301?
GO:2000301 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of synaptic vesicle exocytosis. In other words, it includes molecular events that put a brake on the fusion of synaptic vesicles with the presynaptic membrane, thereby limiting neurotransmitter release. This can occur through direct inhibition of the fusion machinery, modulation of calcium sensing, or regulation of vesicle availability.
Why Is negative regulation of synaptic vesicle exocytosis Important in Cell Biology?
Negative regulation of synaptic vesicle exocytosis is crucial for maintaining synaptic homeostasis and preventing excessive neurotransmitter release that could lead to excitotoxicity. It allows neurons to adapt to changing activity levels and is a key mechanism underlying synaptic plasticity, learning, and memory. Dysregulation of this process has been linked to psychiatric and neurological disorders, making it a target for therapeutic development.
• Prevents excitotoxicity by limiting excessive glutamate release.
• Enables fine-tuning of synaptic strength and plasticity.
• Involved in the pathophysiology of schizophrenia.
• Provides targets for drugs modulating neurotransmission.
• Essential for proper neural circuit development and function.
• Implicated in endocytic recycling and vesicle pool maintenance.
• Regulates presynaptic calcium sensitivity and fusion probability.
• May influence tumorigenesis through CAPS1 in cholangiocarcinoma.
What Happens During negative regulation of synaptic vesicle exocytosis?
Inhibition of SNARE-Mediated Fusion
In simple terms: Proteins put a brake on the molecular machinery that fuses vesicles with the cell membrane.
The core fusion machinery consists of SNARE proteins, including syntaxin-1A and VAMP2, which form a complex to drive vesicle fusion. Negative regulation can occur through proteins that interfere with SNARE complex assembly or stability. For example, Munc18 regulates syntaxin-1A to control vesicle exocytosis, and its modulation can reduce fusion frequency. Additionally, Gβγ subunits directly inhibit SNARE-mediated fusion by interacting with the fusion machinery, providing a molecular brake.
Modulation of Calcium Sensing and Vesicle Priming
In simple terms: The process can be slowed by altering how vesicles sense calcium or get ready to fuse.
Synaptic vesicle exocytosis is triggered by calcium influx and sensed by synaptotagmin-1 (Syt1). Negative regulation can involve proteins that affect Syt1 function or vesicle priming. SV2A controls the surface nanoclustering and endocytic recruitment of Syt1, thereby influencing the efficiency of exocytosis and its regulation. CAPS-1 is another critical factor that anchors the plasma membrane to promote vesicle exocytosis; its dysfunction can lead to reduced exocytosis, but its regulatory role is context-dependent.
Regulation of Vesicle Recycling and Availability
In simple terms: The number of vesicles available for release can be reduced by controlling their recycling.
Negative regulation can also occur by limiting the number of vesicles available for fusion through effects on endocytosis and vesicle reformation. The process of synaptic vesicle endocytosis is tightly coupled to exocytosis, and its inhibition can indirectly reduce exocytosis frequency. Proteins involved in endocytic recycling, such as SV2A, can modulate the pool of releasable vesicles.
Presynaptic Receptor Signaling
In simple terms: Signals from outside the neuron can activate receptors that put a brake on vesicle release.
Neurotransmitters and neuromodulators can activate presynaptic G-protein-coupled receptors (GPCRs), leading to the release of Gβγ subunits that inhibit exocytosis. This is a well-established mechanism for negative regulation, as Gβγ directly interacts with SNARE proteins to reduce fusion. This pathway allows for activity-dependent feedback inhibition of neurotransmitter release.
Key Genes Involved in GO:2000301 negative regulation of synaptic vesicle exocytosis
The following genes and proteins are key players in the negative regulation of synaptic vesicle exocytosis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| STX1A | Syntaxin-1A, SNARE protein; regulated by Munc18 to control exocytosis | Munc18-dependent regulation of exocytosis in hippocampal neurons |
| Munc18 | Regulates syntaxin-1A and SNARE complex assembly | Modulates synaptic vesicle exocytosis |
| Gβγ | G-protein beta-gamma subunits; inhibit SNARE-mediated fusion | Molecular basis for inhibition of synaptic vesicle fusion |
| CAPS-1 | Anchors plasma membrane to promote vesicle exocytosis; may have regulatory roles | DID domain anchors plasma membrane |
| SV2A | Controls surface nanoclustering and endocytic recruitment of Syt1 | Regulates synaptic vesicle recycling |
| VGLUT2 | Vesicular glutamate transporter; substrate recognition and allosteric regulation | Glutamate transport and synaptic vesicle filling |
| Syt1 | Calcium sensor for exocytosis; regulated by SV2A | Synaptic vesicle recycling |
| CAPS1 | Suppresses tumorigenesis in cholangiocarcinoma; involved in exocytosis | Link to cancer |
| Munc18-1 | Essential for synaptic vesicle exocytosis; mutations affect regulation | Regulation of exocytosis |
| VAMP2 | SNARE protein; part of fusion machinery | Target of negative regulation |
| SNAP-25 | SNARE protein; part of fusion machinery | Target of negative regulation |
| Synaptotagmin-1 | Calcium sensor; regulated by SV2A | Synaptic vesicle recycling |
| Complexin | Regulates SNARE-mediated fusion | Potential negative regulator |
| Tomosyn | Inhibits SNARE complex formation | Negative regulation of exocytosis |
| Rab3A | Regulates vesicle docking and fusion | Modulates exocytosis |
| RIM1α | Scaffolding protein at active zone | Regulates vesicle priming |
| Munc13 | Priming factor for vesicle fusion | Regulated by CAPS-1 |
| α-Synuclein | Involved in vesicle trafficking; may regulate exocytosis | Implicated in Parkinson's disease |
How Is negative regulation of synaptic vesicle exocytosis Regulated?
The negative regulation of synaptic vesicle exocytosis is itself subject to regulation by various signaling pathways. For instance, G-protein-coupled receptor signaling leads to Gβγ-mediated inhibition of SNARE fusion. Calcium/calmodulin-dependent pathways can modulate the activity of proteins like CAPS-1 and Munc13. Additionally, endocytic proteins such as SV2A influence the availability of vesicles for release, thereby indirectly regulating exocytosis. The balance between positive and negative regulators is critical for synaptic homeostasis.
negative regulation of synaptic vesicle exocytosis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STX1A | Schizophrenia | KO mice, patient-derived iPSC neurons |
| CAPS1 | Cholangiocarcinoma | KO cell lines, xenograft models |
| SV2A | Epilepsy, neurodegeneration | KO mice, overexpression cell models |
| VGLUT2 | Neuropsychiatric disorders | Conditional KO mice, point mutation knock-in |
| α-Synuclein | Parkinson's disease | Overexpression models, knock-in mice |
Schizophrenia and Synaptic Dysfunction
Synaptic dysfunction is a hallmark of schizophrenia, and abnormalities in the negative regulation of synaptic vesicle exocytosis may contribute to the disease. Altered expression or function of SNARE proteins and their regulators, such as syntaxin-1A and Munc18, have been observed in schizophrenia models. Dysregulation of this process can lead to imbalanced neurotransmitter release, which is thought to underlie some symptoms of schizophrenia.
Cancer: CAPS1 in Cholangiocarcinoma
CAPS1, a protein involved in vesicle exocytosis, has been shown to suppress tumorigenesis in cholangiocarcinoma. While the exact link to negative regulation of synaptic vesicle exocytosis is not fully understood, CAPS1's role in exocytosis may affect cellular processes relevant to cancer. This suggests that proteins regulating exocytosis could have broader implications beyond the nervous system.
Neurodegenerative Diseases
Defects in synaptic vesicle exocytosis and its regulation are increasingly recognized in neurodegenerative diseases such as Parkinson's and Alzheimer's. Proteins like α-synuclein and SV2A are implicated in vesicle trafficking and recycling, and their dysfunction may lead to impaired negative regulation, contributing to synaptic loss.
From negative regulation of synaptic vesicle exocytosis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate synaptic vesicle exocytosis? | CRISPR KO in primary neurons or cell lines |
| How does a point mutation in gene X affect its regulatory function? | Point mutation knock-in via CRISPR |
| What is the effect of overexpressing gene X on exocytosis? | Overexpression cell models |
| Where does protein X localize during negative regulation? | Tagged knock-in (e.g., GFP) for imaging |
| Can we rescue the phenotype by re-expressing wild-type gene X? | Knock-in rescue experiments |
| What are the downstream effectors of gene X? | CRISPR library screening and bioinformatics |
How to Study the negative regulation of synaptic vesicle exocytosis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Synaptic currents, release probability | Assessing negative regulation in neurons |
| TIRF microscopy with pHluorin | Vesicle fusion and recycling events | Live imaging of exocytosis |
| CRISPR knockout | Loss-of-function effects | Identifying negative regulators |
| Overexpression | Gain-of-function effects | Testing if a gene inhibits exocytosis |
| Co-immunoprecipitation | Protein-protein interactions | Mapping regulatory complexes |
| In vitro fusion assay | SNARE-mediated liposome fusion | Direct test of inhibition by Gβγ |
| RNA-seq | Transcriptional changes | Global effects of perturbations |
| Proteomics | Protein abundance and modifications | Identifying downstream effectors |
Electrophysiology
Patch-clamp recordings from presynaptic terminals or postsynaptic neurons can measure the frequency and amplitude of synaptic currents, providing a direct readout of synaptic vesicle exocytosis and its negative regulation.
Live-Cell Imaging
Total internal reflection fluorescence (TIRF) microscopy and pH-sensitive dyes (e.g., pHluorin) allow real-time visualization of vesicle fusion and recycling events, enabling assessment of negative regulators.
Genetic Perturbation
CRISPR/Cas9-mediated knockout, knockdown, or overexpression of candidate genes in neuronal cultures or animal models can reveal their role in negative regulation. Rescue experiments with wild-type or mutant constructs confirm specificity.
Biochemical Assays
Co-immunoprecipitation, pull-down assays, and in vitro fusion assays can identify protein-protein interactions and directly test the inhibitory effects of proteins like Gβγ on SNARE-mediated fusion.
How CRISPR Can Be Used to Study GO:2000301 negative regulation of synaptic vesicle exocytosis
Knockout
CRISPR knockout of candidate genes in neuronal cell lines or primary neurons can determine whether the gene is necessary for negative regulation of synaptic vesicle exocytosis. For example, knocking out Munc18 or syntaxin-1A would be expected to alter exocytosis frequency, but careful controls are needed to distinguish positive and negative roles.
Point Mutation
Introducing specific point mutations (e.g., in the SNARE domain of syntaxin-1A or in Gβγ interaction sites) via CRISPR can dissect the molecular determinants of negative regulation without completely abolishing protein function.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA) of regulatory proteins allows for visualization and biochemical isolation of complexes under native conditions, facilitating the study of their dynamic localization and interactions during negative regulation.
Overexpression
Overexpressing a candidate negative regulator (e.g., Gβγ, tomosyn) in neurons can test whether increased levels reduce exocytosis. This approach can also be used to rescue loss-of-function phenotypes.
How EDITGENE Supports negative regulation of synaptic vesicle exocytosis Research
Researchers studying negative regulation of synaptic vesicle exocytosis-related genes often need to determine whether a candidate gene is causally involved in this process or is merely correlated. This requires precise genetic manipulation and functional assays. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such investigations.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of synaptic vesicle exocytosis research.
Frequently Asked Questions About negative regulation of synaptic vesicle exocytosis
What is GO:2000301?
GO:2000301 is a Gene Ontology term for negative regulation of synaptic vesicle exocytosis, describing any process that stops, prevents, or reduces the frequency, rate, or extent of synaptic vesicle exocytosis.
What genes are involved in negative regulation of synaptic vesicle exocytosis?
Key genes include STX1A, Munc18, Gβγ subunits, CAPS-1, SV2A, and VGLUT2, among others.
How is synaptic vesicle exocytosis negatively regulated?
It can be negatively regulated by direct inhibition of SNARE-mediated fusion (e.g., by Gβγ), modulation of calcium sensing (e.g., via SV2A and Syt1), or limiting vesicle availability through endocytic recycling.
What diseases are associated with dysregulation of this process?
Dysregulation has been linked to schizophrenia, neurodegenerative diseases, and potentially cancer (e.g., CAPS1 in cholangiocarcinoma).
What methods are used to study negative regulation of synaptic vesicle exocytosis?
Common methods include patch-clamp electrophysiology, live-cell imaging with pHluorin, CRISPR knockout/knock-in, and biochemical assays.
What is the role of Munc18 in this process?
Munc18 regulates syntaxin-1A and SNARE complex assembly, and its modulation can reduce the frequency of synaptic vesicle exocytosis.
How does Gβγ inhibit synaptic vesicle fusion?
Gβγ subunits directly interact with SNARE proteins to inhibit fusion, providing a molecular brake on exocytosis.
What is the function of CAPS-1 in exocytosis?
CAPS-1 anchors the plasma membrane to promote vesicle exocytosis, and its DID domain is critical for this function.
Can CRISPR be used to study this process?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the roles of specific genes in negative regulation.
What cell models are suitable for studying negative regulation of synaptic vesicle exocytosis?
Primary hippocampal neurons, PC12 cells, and iPSC-derived neurons are commonly used, along with knockout and knock-in models.
Conclusion
GO:2000301, negative regulation of synaptic vesicle exocytosis, is a critical biological process that ensures proper control of neurotransmitter release. Its dysregulation contributes to various neurological and psychiatric disorders, making it a key area of research. Understanding the molecular players and mechanisms provides opportunities for therapeutic intervention. Advanced CRISPR-based models and functional assays are essential to unravel the complexities of this regulatory process.
References
- 1. Li F et al.. 2025. Substrate recognition and allosteric regulation of synaptic vesicle glutamate transporter VGLUT2.. Nat Struct Mol Biol 32(8):1479-1487 PMID: 40461871
- 2. Mısır E et al.. 2023. Synaptic dysfunction in schizophrenia.. Synapse 77(5):e22276 PMID: 37210696
- 3. Mitchell SJ et al.. 2005. Munc18-dependent regulation of synaptic vesicle exocytosis by syntaxin-1A in hippocampal neurons.. Neuropharmacology 48(3):372-80 PMID: 15721169
- 4. Eitel AR et al.. 2025. Molecular basis for Gβγ-SNARE-mediated inhibition of synaptic vesicle fusion.. J Biol Chem 301(8):110377 PMID: 40523619
- 5. Zhang L et al.. 2025. The DID of CAPS-1 anchors plasma membrane to promote vesicle exocytosis.. J Biol Chem 301(12):110902 PMID: 41197722
- 6. Wang YL et al.. 2017. Putting a brake on synaptic vesicle endocytosis.. Cell Mol Life Sci 74(16):2917-2927 PMID: 28361181
- 7. Small C et al.. 2024. SV2A controls the surface nanoclustering and endocytic recruitment of Syt1 during synaptic vesicle recycling.. J Neurochem 168(9):3188-3208 PMID: 39091022
- 8. Weng S et al.. 2020. CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma.. Dig Dis Sci 65(4):1053-1063 PMID: 31562609
